Vimarsana
Biggest News Aggregation in the World

Page 14 - Breakthrough Therapy News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Breakthrough Therapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Breakthrough Therapy Today - Breaking & Trending Today

HUTCHMED (China) And Innovent's Endometrial Cancer Treatment Granted Priority Review By NMPA - Vimarsana News

HUTCHMED (China) And Innovent's Endometrial Cancer Treatment Granted Priority Review By NMPA

(RTTNews) - HUTCHMED (China) Limited (HCM) and Innovent Biologics Inc. said that the China National Medical Products Administration or 'NMPA' has ...

Mirum Pharmaceuticals' LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada's CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome -April 02, 2024 at 08:38 am EDT - Vimarsana News

Mirum Pharmaceuticals' LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada's CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome -April 02, 2024 at 08:38 am EDT

- Positive HTA recommendation for reimbursement signifies an important milestone towards public funding to treat eligible patients with this rare liver disorder - LIVMARLI is the first and only...

AstraZeneca's Voydeya approved in the US as add-on therapy for PNH patients with EVH - Vimarsana News

AstraZeneca's Voydeya approved in the US as add-on therapy for PNH patients with EVH

AstraZeneca's Voydeya (danicopan) has been approved in the US as add-on therapy for PNH patients with EVH. Find out more about this breakthrough treatment.

AstraZeneca and Daiichi make US progress with latest licence approvals - Vimarsana News

AstraZeneca and Daiichi make US progress with latest licence approvals

AstraZeneca PLC on Tuesday noted significant progress for two of its clinical-stage treatments in the US. The Cambridge, England-based pharmaceutical company said that its Voydeya treatment had been...

AstraZeneca : Voydeya approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular haemolysis in adults with the rare disease PNH - Form 6-K -April 02, 2024 at 08:48 am EDT - Vimarsana News

AstraZeneca : Voydeya approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular haemolysis in adults with the rare disease PNH - Form 6-K -April 02, 2024 at 08:48 am EDT

A9026i FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or...